nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A5—Teniposide—lymphatic system cancer	0.102	0.188	CbGbCtD
Tacrolimus—CYP3A7—Vincristine—lymphatic system cancer	0.0655	0.12	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0655	0.12	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—lymphatic system cancer	0.0492	0.0903	CbGbCtD
Tacrolimus—ABCB1—Mitoxantrone—lymphatic system cancer	0.0465	0.0854	CbGbCtD
Tacrolimus—CYP3A4—Cytarabine—lymphatic system cancer	0.0404	0.0742	CbGbCtD
Tacrolimus—CYP3A4—Teniposide—lymphatic system cancer	0.0398	0.0731	CbGbCtD
Tacrolimus—ALB—Methotrexate—lymphatic system cancer	0.037	0.068	CbGbCtD
Tacrolimus—ABCB1—Vincristine—lymphatic system cancer	0.032	0.0588	CbGbCtD
Tacrolimus—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0279	0.0512	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—lymphatic system cancer	0.0194	0.0356	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—lymphatic system cancer	0.0192	0.0352	CbGbCtD
Tacrolimus—Sepsis—Methotrexate—lymphatic system cancer	0.00026	0.000572	CcSEcCtD
Tacrolimus—Agitation—Carmustine—lymphatic system cancer	0.00026	0.000571	CcSEcCtD
Tacrolimus—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000259	0.000569	CcSEcCtD
Tacrolimus—Asthenia—Fludarabine—lymphatic system cancer	0.000259	0.000569	CcSEcCtD
Tacrolimus—Rash—Teniposide—lymphatic system cancer	0.000259	0.000569	CcSEcCtD
Tacrolimus—Dermatitis—Teniposide—lymphatic system cancer	0.000259	0.000568	CcSEcCtD
Tacrolimus—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000258	0.000566	CcSEcCtD
Tacrolimus—Headache—Teniposide—lymphatic system cancer	0.000257	0.000565	CcSEcCtD
Tacrolimus—Pruritus—Fludarabine—lymphatic system cancer	0.000256	0.000561	CcSEcCtD
Tacrolimus—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000255	0.000561	CcSEcCtD
Tacrolimus—Back pain—Mitoxantrone—lymphatic system cancer	0.000255	0.000559	CcSEcCtD
Tacrolimus—Leukopenia—Carmustine—lymphatic system cancer	0.000254	0.000557	CcSEcCtD
Tacrolimus—Anorexia—Bleomycin—lymphatic system cancer	0.000252	0.000554	CcSEcCtD
Tacrolimus—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000252	0.000553	CcSEcCtD
Tacrolimus—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00025	0.00055	CcSEcCtD
Tacrolimus—Anaemia—Vincristine—lymphatic system cancer	0.00025	0.000549	CcSEcCtD
Tacrolimus—Agitation—Vincristine—lymphatic system cancer	0.000249	0.000546	CcSEcCtD
Tacrolimus—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000248	0.000545	CcSEcCtD
Tacrolimus—Photosensitivity—Methotrexate—lymphatic system cancer	0.000248	0.000545	CcSEcCtD
Tacrolimus—Hypotension—Bleomycin—lymphatic system cancer	0.000247	0.000543	CcSEcCtD
Tacrolimus—Diarrhoea—Fludarabine—lymphatic system cancer	0.000247	0.000543	CcSEcCtD
Tacrolimus—Convulsion—Carmustine—lymphatic system cancer	0.000245	0.000539	CcSEcCtD
Tacrolimus—Hypertension—Carmustine—lymphatic system cancer	0.000245	0.000537	CcSEcCtD
Tacrolimus—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000244	0.000536	CcSEcCtD
Tacrolimus—Nausea—Teniposide—lymphatic system cancer	0.000244	0.000536	CcSEcCtD
Tacrolimus—Anaemia—Mitoxantrone—lymphatic system cancer	0.000243	0.000534	CcSEcCtD
Tacrolimus—Vertigo—Vincristine—lymphatic system cancer	0.000243	0.000533	CcSEcCtD
Tacrolimus—Hepatic failure—Methotrexate—lymphatic system cancer	0.000242	0.000532	CcSEcCtD
Tacrolimus—Leukopenia—Vincristine—lymphatic system cancer	0.000242	0.000531	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000241	0.00053	CcSEcCtD
Tacrolimus—Chest pain—Carmustine—lymphatic system cancer	0.000241	0.000529	CcSEcCtD
Tacrolimus—Myalgia—Carmustine—lymphatic system cancer	0.000241	0.000529	CcSEcCtD
Tacrolimus—Anxiety—Carmustine—lymphatic system cancer	0.00024	0.000528	CcSEcCtD
Tacrolimus—Paraesthesia—Bleomycin—lymphatic system cancer	0.000238	0.000522	CcSEcCtD
Tacrolimus—Malaise—Mitoxantrone—lymphatic system cancer	0.000237	0.000521	CcSEcCtD
Tacrolimus—Dyspnoea—Bleomycin—lymphatic system cancer	0.000236	0.000518	CcSEcCtD
Tacrolimus—Renal failure acute—Methotrexate—lymphatic system cancer	0.000236	0.000518	CcSEcCtD
Tacrolimus—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000236	0.000517	CcSEcCtD
Tacrolimus—Convulsion—Vincristine—lymphatic system cancer	0.000234	0.000514	CcSEcCtD
Tacrolimus—Hypertension—Vincristine—lymphatic system cancer	0.000233	0.000513	CcSEcCtD
Tacrolimus—Confusional state—Carmustine—lymphatic system cancer	0.000233	0.000512	CcSEcCtD
Tacrolimus—Oedema—Carmustine—lymphatic system cancer	0.000231	0.000508	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000231	0.000507	CcSEcCtD
Tacrolimus—Decreased appetite—Bleomycin—lymphatic system cancer	0.00023	0.000505	CcSEcCtD
Tacrolimus—Myalgia—Vincristine—lymphatic system cancer	0.00023	0.000505	CcSEcCtD
Tacrolimus—Cough—Mitoxantrone—lymphatic system cancer	0.00023	0.000504	CcSEcCtD
Tacrolimus—Infection—Carmustine—lymphatic system cancer	0.00023	0.000504	CcSEcCtD
Tacrolimus—Vomiting—Fludarabine—lymphatic system cancer	0.00023	0.000504	CcSEcCtD
Tacrolimus—Convulsion—Mitoxantrone—lymphatic system cancer	0.000228	0.000501	CcSEcCtD
Tacrolimus—Rash—Fludarabine—lymphatic system cancer	0.000228	0.0005	CcSEcCtD
Tacrolimus—Dermatitis—Fludarabine—lymphatic system cancer	0.000228	0.0005	CcSEcCtD
Tacrolimus—Hypertension—Mitoxantrone—lymphatic system cancer	0.000227	0.000499	CcSEcCtD
Tacrolimus—Pain—Bleomycin—lymphatic system cancer	0.000226	0.000497	CcSEcCtD
Tacrolimus—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000226	0.000497	CcSEcCtD
Tacrolimus—Headache—Fludarabine—lymphatic system cancer	0.000226	0.000497	CcSEcCtD
Tacrolimus—Tachycardia—Carmustine—lymphatic system cancer	0.000226	0.000495	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000225	0.000494	CcSEcCtD
Tacrolimus—Chest pain—Mitoxantrone—lymphatic system cancer	0.000224	0.000492	CcSEcCtD
Tacrolimus—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000224	0.000492	CcSEcCtD
Tacrolimus—Myalgia—Mitoxantrone—lymphatic system cancer	0.000224	0.000492	CcSEcCtD
Tacrolimus—Anxiety—Mitoxantrone—lymphatic system cancer	0.000223	0.00049	CcSEcCtD
Tacrolimus—Discomfort—Mitoxantrone—lymphatic system cancer	0.000222	0.000486	CcSEcCtD
Tacrolimus—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000221	0.000484	CcSEcCtD
Tacrolimus—Oedema—Vincristine—lymphatic system cancer	0.000221	0.000484	CcSEcCtD
Tacrolimus—Anorexia—Carmustine—lymphatic system cancer	0.00022	0.000484	CcSEcCtD
Tacrolimus—Infection—Vincristine—lymphatic system cancer	0.000219	0.000481	CcSEcCtD
Tacrolimus—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000218	0.000479	CcSEcCtD
Tacrolimus—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000218	0.000478	CcSEcCtD
Tacrolimus—Confusional state—Mitoxantrone—lymphatic system cancer	0.000217	0.000476	CcSEcCtD
Tacrolimus—Nervous system disorder—Vincristine—lymphatic system cancer	0.000216	0.000475	CcSEcCtD
Tacrolimus—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000216	0.000474	CcSEcCtD
Tacrolimus—Hypotension—Carmustine—lymphatic system cancer	0.000216	0.000474	CcSEcCtD
Tacrolimus—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000215	0.000472	CcSEcCtD
Tacrolimus—Oedema—Mitoxantrone—lymphatic system cancer	0.000215	0.000472	CcSEcCtD
Tacrolimus—Nausea—Fludarabine—lymphatic system cancer	0.000215	0.000471	CcSEcCtD
Tacrolimus—Infection—Mitoxantrone—lymphatic system cancer	0.000214	0.000469	CcSEcCtD
Tacrolimus—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000213	0.000468	CcSEcCtD
Tacrolimus—Shock—Mitoxantrone—lymphatic system cancer	0.000211	0.000464	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000211	0.000462	CcSEcCtD
Tacrolimus—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00021	0.000462	CcSEcCtD
Tacrolimus—Urticaria—Bleomycin—lymphatic system cancer	0.00021	0.000462	CcSEcCtD
Tacrolimus—Anorexia—Vincristine—lymphatic system cancer	0.00021	0.000462	CcSEcCtD
Tacrolimus—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00021	0.00046	CcSEcCtD
Tacrolimus—Body temperature increased—Bleomycin—lymphatic system cancer	0.000209	0.00046	CcSEcCtD
Tacrolimus—Insomnia—Carmustine—lymphatic system cancer	0.000209	0.000459	CcSEcCtD
Tacrolimus—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000209	0.000458	CcSEcCtD
Tacrolimus—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000208	0.000456	CcSEcCtD
Tacrolimus—Paraesthesia—Carmustine—lymphatic system cancer	0.000208	0.000456	CcSEcCtD
Tacrolimus—Mood swings—Methotrexate—lymphatic system cancer	0.000206	0.000453	CcSEcCtD
Tacrolimus—Hypotension—Vincristine—lymphatic system cancer	0.000206	0.000453	CcSEcCtD
Tacrolimus—Dyspnoea—Carmustine—lymphatic system cancer	0.000206	0.000452	CcSEcCtD
Tacrolimus—Somnolence—Carmustine—lymphatic system cancer	0.000206	0.000451	CcSEcCtD
Tacrolimus—Anorexia—Mitoxantrone—lymphatic system cancer	0.000205	0.00045	CcSEcCtD
Tacrolimus—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000201	0.000442	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000201	0.000441	CcSEcCtD
Tacrolimus—Decreased appetite—Carmustine—lymphatic system cancer	0.000201	0.000441	CcSEcCtD
Tacrolimus—Hypotension—Mitoxantrone—lymphatic system cancer	0.000201	0.000441	CcSEcCtD
Tacrolimus—Insomnia—Vincristine—lymphatic system cancer	0.0002	0.000438	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0002	0.000438	CcSEcCtD
Tacrolimus—Paraesthesia—Vincristine—lymphatic system cancer	0.000198	0.000435	CcSEcCtD
Tacrolimus—Pain—Carmustine—lymphatic system cancer	0.000198	0.000434	CcSEcCtD
Tacrolimus—Constipation—Carmustine—lymphatic system cancer	0.000198	0.000434	CcSEcCtD
Tacrolimus—Breast disorder—Methotrexate—lymphatic system cancer	0.000197	0.000432	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000196	0.000431	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000196	0.00043	CcSEcCtD
Tacrolimus—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000195	0.000428	CcSEcCtD
Tacrolimus—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000193	0.000424	CcSEcCtD
Tacrolimus—Decreased appetite—Vincristine—lymphatic system cancer	0.000192	0.000421	CcSEcCtD
Tacrolimus—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000192	0.000421	CcSEcCtD
Tacrolimus—Somnolence—Mitoxantrone—lymphatic system cancer	0.000191	0.000419	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000191	0.000418	CcSEcCtD
Tacrolimus—Feeling abnormal—Carmustine—lymphatic system cancer	0.000191	0.000418	CcSEcCtD
Tacrolimus—Fatigue—Vincristine—lymphatic system cancer	0.00019	0.000418	CcSEcCtD
Tacrolimus—Asthenia—Bleomycin—lymphatic system cancer	0.00019	0.000417	CcSEcCtD
Tacrolimus—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000189	0.000415	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000189	0.000415	CcSEcCtD
Tacrolimus—Constipation—Vincristine—lymphatic system cancer	0.000189	0.000414	CcSEcCtD
Tacrolimus—Pain—Vincristine—lymphatic system cancer	0.000189	0.000414	CcSEcCtD
Tacrolimus—Asthma—Methotrexate—lymphatic system cancer	0.000188	0.000413	CcSEcCtD
Tacrolimus—Pruritus—Bleomycin—lymphatic system cancer	0.000187	0.000411	CcSEcCtD
Tacrolimus—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000187	0.00041	CcSEcCtD
Tacrolimus—Fatigue—Mitoxantrone—lymphatic system cancer	0.000185	0.000407	CcSEcCtD
Tacrolimus—Pancreatitis—Methotrexate—lymphatic system cancer	0.000185	0.000405	CcSEcCtD
Tacrolimus—Pain—Mitoxantrone—lymphatic system cancer	0.000184	0.000403	CcSEcCtD
Tacrolimus—Constipation—Mitoxantrone—lymphatic system cancer	0.000184	0.000403	CcSEcCtD
Tacrolimus—Body temperature increased—Carmustine—lymphatic system cancer	0.000183	0.000401	CcSEcCtD
Tacrolimus—Abdominal pain—Carmustine—lymphatic system cancer	0.000183	0.000401	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00018	0.000396	CcSEcCtD
Tacrolimus—Pancytopenia—Methotrexate—lymphatic system cancer	0.000179	0.000393	CcSEcCtD
Tacrolimus—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000177	0.000389	CcSEcCtD
Tacrolimus—Dysuria—Methotrexate—lymphatic system cancer	0.000176	0.000387	CcSEcCtD
Tacrolimus—Neutropenia—Methotrexate—lymphatic system cancer	0.000176	0.000387	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000176	0.000386	CcSEcCtD
Tacrolimus—Body temperature increased—Vincristine—lymphatic system cancer	0.000174	0.000383	CcSEcCtD
Tacrolimus—Abdominal pain—Vincristine—lymphatic system cancer	0.000174	0.000383	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000172	0.000377	CcSEcCtD
Tacrolimus—Urticaria—Mitoxantrone—lymphatic system cancer	0.000171	0.000375	CcSEcCtD
Tacrolimus—Hypersensitivity—Carmustine—lymphatic system cancer	0.00017	0.000374	CcSEcCtD
Tacrolimus—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00017	0.000373	CcSEcCtD
Tacrolimus—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00017	0.000373	CcSEcCtD
Tacrolimus—Pneumonia—Methotrexate—lymphatic system cancer	0.000169	0.000371	CcSEcCtD
Tacrolimus—Vomiting—Bleomycin—lymphatic system cancer	0.000168	0.00037	CcSEcCtD
Tacrolimus—Infestation NOS—Methotrexate—lymphatic system cancer	0.000168	0.000369	CcSEcCtD
Tacrolimus—Infestation—Methotrexate—lymphatic system cancer	0.000168	0.000369	CcSEcCtD
Tacrolimus—Depression—Methotrexate—lymphatic system cancer	0.000167	0.000368	CcSEcCtD
Tacrolimus—Rash—Bleomycin—lymphatic system cancer	0.000167	0.000367	CcSEcCtD
Tacrolimus—Dermatitis—Bleomycin—lymphatic system cancer	0.000167	0.000366	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000166	0.000365	CcSEcCtD
Tacrolimus—Asthenia—Carmustine—lymphatic system cancer	0.000166	0.000364	CcSEcCtD
Tacrolimus—Renal failure—Methotrexate—lymphatic system cancer	0.000165	0.000362	CcSEcCtD
Tacrolimus—Stomatitis—Methotrexate—lymphatic system cancer	0.000164	0.000359	CcSEcCtD
Tacrolimus—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000163	0.000358	CcSEcCtD
Tacrolimus—Hypersensitivity—Vincristine—lymphatic system cancer	0.000163	0.000357	CcSEcCtD
Tacrolimus—Sweating—Methotrexate—lymphatic system cancer	0.000161	0.000353	CcSEcCtD
Tacrolimus—Haematuria—Methotrexate—lymphatic system cancer	0.00016	0.000351	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000159	0.000349	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—lymphatic system cancer	0.000158	0.000348	CcSEcCtD
Tacrolimus—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000158	0.000348	CcSEcCtD
Tacrolimus—Asthenia—Vincristine—lymphatic system cancer	0.000158	0.000348	CcSEcCtD
Tacrolimus—Diarrhoea—Carmustine—lymphatic system cancer	0.000158	0.000347	CcSEcCtD
Tacrolimus—Nausea—Bleomycin—lymphatic system cancer	0.000157	0.000345	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000157	0.000344	CcSEcCtD
Tacrolimus—Asthenia—Mitoxantrone—lymphatic system cancer	0.000154	0.000339	CcSEcCtD
Tacrolimus—Dizziness—Carmustine—lymphatic system cancer	0.000153	0.000336	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—lymphatic system cancer	0.000151	0.000333	CcSEcCtD
Tacrolimus—Diarrhoea—Vincristine—lymphatic system cancer	0.000151	0.000331	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—lymphatic system cancer	0.000151	0.000331	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—lymphatic system cancer	0.000151	0.000331	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—lymphatic system cancer	0.00015	0.000328	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000149	0.000327	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—lymphatic system cancer	0.000148	0.000324	CcSEcCtD
Tacrolimus—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000147	0.000323	CcSEcCtD
Tacrolimus—Vomiting—Carmustine—lymphatic system cancer	0.000147	0.000323	CcSEcCtD
Tacrolimus—Dizziness—Vincristine—lymphatic system cancer	0.000146	0.00032	CcSEcCtD
Tacrolimus—Rash—Carmustine—lymphatic system cancer	0.000146	0.00032	CcSEcCtD
Tacrolimus—Dermatitis—Carmustine—lymphatic system cancer	0.000146	0.00032	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—lymphatic system cancer	0.000145	0.000319	CcSEcCtD
Tacrolimus—Headache—Carmustine—lymphatic system cancer	0.000145	0.000318	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000143	0.000313	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—lymphatic system cancer	0.000141	0.000309	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—lymphatic system cancer	0.000141	0.000309	CcSEcCtD
Tacrolimus—Vomiting—Vincristine—lymphatic system cancer	0.00014	0.000308	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00014	0.000307	CcSEcCtD
Tacrolimus—Rash—Vincristine—lymphatic system cancer	0.000139	0.000305	CcSEcCtD
Tacrolimus—Dermatitis—Vincristine—lymphatic system cancer	0.000139	0.000305	CcSEcCtD
Tacrolimus—Headache—Vincristine—lymphatic system cancer	0.000138	0.000304	CcSEcCtD
Tacrolimus—Nausea—Carmustine—lymphatic system cancer	0.000137	0.000301	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—lymphatic system cancer	0.000137	0.0003	CcSEcCtD
Tacrolimus—Vomiting—Mitoxantrone—lymphatic system cancer	0.000137	0.0003	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—lymphatic system cancer	0.000136	0.000299	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000136	0.000298	CcSEcCtD
Tacrolimus—Rash—Mitoxantrone—lymphatic system cancer	0.000136	0.000297	CcSEcCtD
Tacrolimus—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000135	0.000297	CcSEcCtD
Tacrolimus—Chills—Methotrexate—lymphatic system cancer	0.000135	0.000297	CcSEcCtD
Tacrolimus—Headache—Mitoxantrone—lymphatic system cancer	0.000135	0.000296	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—lymphatic system cancer	0.000133	0.000292	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—lymphatic system cancer	0.000132	0.00029	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—lymphatic system cancer	0.000131	0.000288	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—lymphatic system cancer	0.000131	0.000288	CcSEcCtD
Tacrolimus—Nausea—Vincristine—lymphatic system cancer	0.000131	0.000288	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—lymphatic system cancer	0.000128	0.000282	CcSEcCtD
Tacrolimus—Nausea—Mitoxantrone—lymphatic system cancer	0.000128	0.00028	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—lymphatic system cancer	0.000127	0.000279	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—lymphatic system cancer	0.000124	0.000271	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000122	0.000267	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—lymphatic system cancer	0.000121	0.000266	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—lymphatic system cancer	0.000118	0.00026	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—lymphatic system cancer	0.000118	0.000259	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—lymphatic system cancer	0.000117	0.000258	CcSEcCtD
Tacrolimus—Cough—Methotrexate—lymphatic system cancer	0.000114	0.000251	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—lymphatic system cancer	0.000114	0.00025	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—lymphatic system cancer	0.000112	0.000245	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—lymphatic system cancer	0.000112	0.000245	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—lymphatic system cancer	0.000112	0.000245	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000111	0.000244	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—lymphatic system cancer	0.00011	0.000242	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—lymphatic system cancer	0.000108	0.000237	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000107	0.000235	CcSEcCtD
Tacrolimus—Infection—Methotrexate—lymphatic system cancer	0.000106	0.000234	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000105	0.000231	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000105	0.00023	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—lymphatic system cancer	0.000104	0.000228	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000104	0.000227	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—lymphatic system cancer	0.000102	0.000224	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—lymphatic system cancer	0.0001	0.00022	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	9.76e-05	0.000214	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—lymphatic system cancer	9.69e-05	0.000213	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—lymphatic system cancer	9.62e-05	0.000211	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—lymphatic system cancer	9.55e-05	0.00021	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—lymphatic system cancer	9.52e-05	0.000209	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—lymphatic system cancer	9.43e-05	0.000207	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—lymphatic system cancer	9.31e-05	0.000204	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	9.25e-05	0.000203	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—lymphatic system cancer	9.23e-05	0.000203	CcSEcCtD
Tacrolimus—Pain—Methotrexate—lymphatic system cancer	9.16e-05	0.000201	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—lymphatic system cancer	8.82e-05	0.000194	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—lymphatic system cancer	8.76e-05	0.000192	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—lymphatic system cancer	8.51e-05	0.000187	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—lymphatic system cancer	8.47e-05	0.000186	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—lymphatic system cancer	8.47e-05	0.000186	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—lymphatic system cancer	7.89e-05	0.000173	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—lymphatic system cancer	7.68e-05	0.000169	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—lymphatic system cancer	7.58e-05	0.000166	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—lymphatic system cancer	7.33e-05	0.000161	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—lymphatic system cancer	7.08e-05	0.000155	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—lymphatic system cancer	6.81e-05	0.000149	CcSEcCtD
Tacrolimus—Rash—Methotrexate—lymphatic system cancer	6.75e-05	0.000148	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—lymphatic system cancer	6.75e-05	0.000148	CcSEcCtD
Tacrolimus—Headache—Methotrexate—lymphatic system cancer	6.71e-05	0.000147	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—lymphatic system cancer	6.36e-05	0.00014	CcSEcCtD
